Galmed Pharmaceuticals Ltd. EOCN

3.63 0.01 0.28% as of 25 Sep
Market cap
$3.8M
P/E
0.0×
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
4.92 4.04 3.97 3.29
Current Ratio
7.98 6.55 7.71 4.16
Net Debt/EBITDA
5.56 3.65 3.84 3.20
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.02 0.40 1.33 0.78
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.35
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(2.84) (3.61) (3.08) (2.23)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(2.84) (3.61) (3.08) (2.23)
Cash per Share
17.02 20.66 9.47 9.37
Shareholders Equity per Share
28.00 29.29 16.93 13.38
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
28.00 29.29 16.93 13.38
Free Cash Flow
(1.93) (1.94) (2.54) (2.13)
Working Capital
17.25 15.78 13.95 8.90
Net Current Asset Value
17.25 15.78 13.95 6.17
EV/EBIT
— — — —
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Receivables
0.49 0.51 0.45 0.38
Average Payables
1.51 1.66 1.52 1.63
Average Assets
21.27 18.56 17.36 20.61
Average Common Equity
18.77 16.05 15.41 16.63

Fold the line items

Columns are period end dates